Skip to main content

Market Overview

Amgen, Neumora Collaborate On Precision Therapies for Brain Diseases

Amgen, Neumora Collaborate On Precision Therapies for Brain Diseases
  • Amgen Inc (NASDAQ: AMGN) and Neumora Therapeutics Inc have announced a strategic collaboration to advance neuroscience discovery, development, and commercialization. 
  • The companies will collaborate on programs by applying Neumora's proprietary precision neuroscience platform to insights generated by Amgen's deCODE genetics and human data research capabilities. 
  • Deal terms for the collaboration were not disclosed.
  • In addition, Neumora has received a $100 million equity investment from Amgen and acquired exclusive global rights to Amgen programs targeting casein kinase 1 delta and glucocerebrosidase for neurodegenerative diseases.
  • Related: Amgen's Lumakras Combo Therapy Shows Improved Response Rate In Colorectal Cancer.
  • Price Action: AMGN stock closed 0.89% lower at $209.98 on Wednesday.

Related Articles (AMGN)

View Comments and Join the Discussion!

Posted-In: Briefs neuroscienceBiotech News Health Care Contracts General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at